

**International Journal of Biology, Pharmacy
and Allied Sciences (IJBPAS)**

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

FORMULATION AND EVALUATION OF DICYCLOMINE HCL-LOADED NANOTRANSFERSOMES DELIVERY SYSTEM

KANDUKURI SUSHMA* AND Dr. LALIT LATA JHA

Parul University, School of Pharmacy, Dist. Vadodara, Gujarat (India)

*Corresponding Authors: Kandukuri Sushma: Email: Sushma.Pharmaceutics@gmail.com

Received 19th May 2021; Revised 4th June 2021; Accepted 9th July 2021; Available online 25th Sept. 2021

<https://doi.org/10.31032/IJBPAS/2021/10.9.1023>

ABSTRACT

The purpose of the current study was to develop Dicyclomine HCl (DIC; a antispasmodic used for treatment of spasticity) loaded nanotransfersomes intended for rectal administration, aiming to bypass the hepatic first- pass metabolism. DIC-loaded nanotransfersomes were prepared by thin-film hydration method followed by characterization for various parameters including entrapment efficiency, vesicle diameter, in vitro release and ex vivo permeation studies. Transfersomal formulation composed of phosphatidylcholine and Tween 80 at a weight ratio of (85:15) gave a satisfactory results. It exhibited encapsulation efficiency of 52.39%, mean diameter of 150.33 nm, controlled drug release over 8 h and good permeation characteristics. Optimum formula was then incorporated into Pluronic-based thermoreversible gel using hydroxypropyl methylcellulose (HPMC) as a mucoadhesive polymer. Pharmacokinetic study was performed by rectal administration of transfersomes-loaded in situ gel to rabbits and compared with oral drug solution and rectal DIC in situ gel. The pharmacokinetic study revealed that the transfersomal formulation successively enhanced the bioavailability of DIC by about 2.18-fold and increased $t_{1/2}$ to about 10 h as compared to oral solution. It can be concluded that encapsulation of DIC into nanotransfersomes can achieve a dual purpose of prolonged DIC release and enhanced bioavailability and so may be considered as a promising drug delivery system for the treatment of spasticity.

INTRODUCTION

Dicyclomine HCl (DIC) is a antispasmodic used for treatment of spasticity (Wagstaff & Bryson, 1997). DIC suffers from rapid and extensive hepatic first-pass metabolism after oral administration which results in a poor drug bioavailability (34–40%). Also, DIC exhibits a short elimination half-life of 2.5 h (Pendekal & Tegginamat, 2012, El-Mahrouk et al., 2014). The matters that necessitate frequent administration of DIC which may result in poor patient compliance. Transfersomes, the ultraflexible liposomes, composed of a bilayer former as phospholipid and edge activator. Transfersomes are more elastic than the conventional liposomes (Jain et al., 2003). Elasticity in these vesicles is attributed to the presence of an edge activator which is able to weaken the lipid bilayer of the vesicles and increase their deformability and flexibility. Edge activators are single chain surfactants with a high radius of curvature (Baldrick, 2000). Spans, Tweens, dipotassium glycyrrhizinate, sodium cholate and sodium deoxycholate were employed as edge activators (Cevc & Blume, 2003). Transfersomes, being deformable, can squeeze themselves through pores in the biological membranes, which are too much

smaller than their own diameters.

Rectal route offers a useful, noninvasive alternative route of administration when local or systemic effect is intended. The rectum provides a relatively constant environment for drug delivery that allows a constant steady-state concentration of drug in plasma and partially avoids gastrointestinal (GI) absorption difficulties and hepatic first-pass metabolism (El-Leithy *et al.*, 2010).

However, conventional solid suppositories are usually accompanied with discomfort that may lead to poor compliance and patient refusal. Moreover, if they lack mucoadhesion, conventional suppositories might reach the end of the colon. Therefore, incorporated drugs may be exposed to first-pass metabolism (Huang *et al.*, 1987; Özgüney *et al.*, 2014). Therefore, another rectal dosage form that is easy to administer and with mucoadhesive properties has to be used. So mucoadhesive in situ gels were used. The potential of thermosensitive in situ gels as a drug delivery system has been widely studied. They were investigated for use as delivery system for rectal, topical, nasal, ophthalmic, subcutaneous and intraperitoneal administration (Miyazaki *et al.*, 1998).

The aim of the present study was to assess the possibility of the development of a new

vesicle-loaded gelling system as a carrier for the rectal delivery of DIC as an effective treatment for spasticity, overcoming the drawbacks of oral delivery. This was achieved by comprehensive *in vitro* and *in vivo* evaluation of the developed systems in an attempt to attain an optimized, effective and promising delivery system.

MATERIAL AND METHODS

Materials

DIC was obtained as a gift sample from Sigma Pharmaceutical Industries (Egypt). L- α -phosphatidylcholine (PC), cholesterol, sorbitan monooleate (Span 80), sodium deoxycholate (SDC), polyoxyethylene lauryl ether (Brij 35), poloxamer 407 (P407), poloxamer 188 (P188), hydroxypropyl methylcellulose (HPMC, K15M) were purchased from Sigma-Aldrich (St Louis, MO). TDialysis bags with a molecular weight cutoff of 12 000 Da were purchased from SERVA Electrophoresis GmbH (Heidelberg, Germany). Tolterodine was kindly supplied from Sabaa Pharma (Egypt). All other ingredients used were of analytical grade.

Preparation of DIC-loaded transfersomal vesicles

Different transfersomal formulations were

prepared by conventional rotary evaporation method described by Cevc *et al.* (1997) with some modification. Briefly, the lipid phase consisted of phospholipid, edge activators and cholesterol was dissolved in chloroform (5 ml). The organic solvent was removed under vacuum using a rotary evaporator (Stuart, RE300, Wolf Laboratories, UK) in a 55 °C water bath at 100 rpm. The formed film was maintained for 2 h in a desiccator under vacuum for complete removal of traces of solvent. The film was then hydrated with 10 ml phosphate buffer solution containing 10 mg DIC and allowed to rotate at 80 rpm for 1 h under normal pressure. For particle size reduction, the obtained transfersomal suspensions were then sonicated for 30 min using a bath sonicator.

Table 1 demonstrates the composition of the prepared TIZ- loaded transfersomes, where Span 80, Tween 80, Brij 35 and SDC were used as edge activators along with L- α -PC as a bilayer former.

Characterization of DIC vesicles

Determination of DIC entrapment efficiency (EE %)

First, free DIC was separated by cooling centrifugation at 22 000 rpm for 1 h using cooling centrifuge (Sigma, 3–30K, Germany) at 4 °C. The obtained precipitate was washed

twice with distilled water and re-centrifuged again to ensure complete removal of the free un-entrapped drug.

The amount of entrapped DIC was determined by disruption of the separated vesicles with 1% w/v Triton X-100 in phosphate buffer (pH 7.4) with sonication and heating to about 60 C to ensure complete lysis of the vesicles.

Furthermore, it was centrifuged for 20 min at 8000 rpm for precipitation of any debris. After a suitable dilution with phosphate buffer solution (pH 7.4), the solution was analyzed spectrophotometrically for the drug content at 319 nm using spectrophotometer (Jasco V-530, Japan). DIC EE% was calculated using the following formula (Ghanbarzadeh *et al.*, 2015):

$$EE\% = \frac{\text{Entrapped drug}}{\text{Total drug}} \times 100$$

Determination of particle size and polydispersity index (PDI)

The mean diameter and PDI of the prepared vesicles were estimated using the dynamic light scattering method (Mahmood *et al.*, 2014). One milliliter transfersomal suspension was diluted to 10 ml with distilled water and measured by a Malvern Zetasizer at 25

°C (Zetasizer Nano ZS, Malvern Instruments, Malvern, UK). Three replicates of each sample were taken.

In vitro release studies

The in vitro release profiles of DIC-loaded transfersomal formulations were conducted and compared with the free drug (FG) solution using a fabricated vertical diffusion Franz cells with an effective diffusion area of 5 cm². An accurate volumes of the transfersomal suspensions and drug solution, equivalent to 3 mg of drug, were placed in donor compartment and allowed to diffuse through a presoaked dialysis membrane (Mol. Wt cutoff ¼ 12 000 Da) into 50 ml phosphate buffer solution with pH 7.4 (El-Kamel & El- Khatib, 2006) as a receptor medium.

At predetermined time intervals along 8 h (480 min) test period, 1 ml of samples was withdrawn from the receptor medium, replaced by an equal volume of buffer, filtered and analyzed spectrophotometrically at 319 nm.

Ex vivo permeation studies

Prepared transfersomal formulations were subjected to in vitro permeation study and permeation profile of DIC was established. The study was performed according to the procedures previously described by Kamel *et al.* (2013) with slight modifications using a

fabricated Franz diffusion cell stirred at 100 rpm for up to 24 h with cattle rectum as a diffusion membrane and temperature maintained at 37 ± 0.5 °C and the receptor compartment contains 50 ml phosphate buffer solution pH 7.4 (El-Kamel & El-Khatib, 2006). At a predetermined time interval, 1 ml sample was withdrawn and replaced with equal volume of freshly prepared phosphate buffer to maintain a constant volume. Samples were filtered, suitably diluted and spectrophotometrically analyzed at 319 nm for the cumulative amount permeated of DIC. All experiments were done in triplicate and the mean values \pm SD are listed in **Table 1**.

The cumulative amount of DIC permeated was plotted as a function of time and rectal permeation parameters such as cumulative amount of drug permeated per rectum unit area during 24 h (Q_{24} in mg/cm^{-2}), flux (J in $\text{mg}/\text{cm}^2/\text{h}$, Equation 1), permeability coefficient (K_p in cm/h , Equation 2) were calculated. Lag time can be determined from the X-intercept of the linear portion of the plot.

One drop of transfersomal dispersion was dropped on a carbon grid as a thin film

and allowed to dry. The film was then negatively stained with 1% phosphotungstic acid; excess liquid was removed by filter paper and finally allowed to dry. The air-dried sample was examined by TEM analyzer operating at an accelerating voltage of 80 kV (Joel, Tokyo, Japan) (Abdelrahman *et al.*, 2015; Aboud *et al.*, 2015).

Preparation of thermosensitive in situ gel

The selected transfersomal formula F5 was incorporated in a $J^{1/4}$ Amount of drug permeated Time \times area of the membrane $\delta 1p$ thermosensitive in situ gel with the composition of (21:3:0.8%) for

P407:P188:HPMC. In situ gel

$K_p^{1/4} \frac{dQ}{dt} A C_d$

$\delta 2p$ formulations were prepared on a weight/volume basis using the cold method described by Schmolka *et al.* (Schmolka, 1972; Pan & Yang, 2011) with slight modification. Briefly, mucoadhesive polymer was where $dQ/dt^{1/4}$ amount of drug/time which obtained from the slope of the straight portion of the plot, A is the diffusion area (5 cm^2) and C_d is the concentration of the drug in the donor compartment (Al-Mahallawi *et al.*, 2014; Gonz lez-Rodr guez *et al.*, 2016).

Selection of the optimized formula

The optimized formula of transfersomal suspension was selected on the basis of a good EE%, optimal vesicle size, high percentage of drug released and maximum cumulative amount permeated. The selected formula was characterized by transmission electron microscopy (TEM) and eventually incorporated into thermosensitive gel.

Transmission electron microscopy

Visualization and morphological examination of the selected transfersomal formula F5 was conducted by means of TEM. weighed, slowly sprinkled on accurately measured volume of freshly prepared transfersomal suspension of F5 for preparation of transfer-somes-loaded in situ gel (TG). Mixture was gently stirred using magnetic stirrer till completely dissolve. Then, mixture of P407 and P188 (21:3%w/v) was dispersed, gently mixed and stored in refrigerator at 4 °C till poloxamer granules were completely dissolved and a clear homogenous solution was obtained.

Histopathological evaluation

Nine Albino Wister rats weighing 150–200 g were divided into three groups (three rats per each group) and fasted for 24 h prior to the experiment with free access to water to reduce the fecal matter in

the rectum.

Group A was the control, whereas groups B and C received FG and TG, respectively. At 8 h after administration; animals were sacrificed, rectum was isolated, rinsed with saline and fixed in 10% formalin buffer. Furthermore, rectum segments were embedded in paraffin and cut into slices. The slices were stained with hematoxylin and eosin and observed under light microscope (El-Leithy *et al.*, 2010; Ud Din *et al.*, 2015). This evaluation was performed in a blinded manner by an experienced veterinary histopathologist.

Pharmacokinetic study

Animals

For each examined formulation, three New Zealand white male rabbits, weighing 2–2.5 kg were used. Rabbits were fasted for 24 h prior to the experiment with free access to water to avoid defecation during the experiment. Rabbits were conscious during dosing and the whole duration of the experiment. Rabbits were held in restrainers during blood sampling. This study was performed according to the guidelines of the local animal ethical committee.

Study design

A single dose equivalent to 1 mg/kg DIC was administered to rabbits using randomized crossover design in three stages with 1

week washout period in between.

Dosage and dose administration

The three groups of rabbits received a dose of 1 mg/kg of DIC from different formulations irrespective of the route of administration. Formulations used were as follows: DIC solution in purified water for oral administration, in situ gel of FG and in situ gel of transfersomal formula F5 (TG) both for rectal administration. Gel formulations were administered 4 cm above the anus using a stomach Sonde needle fitted to a disposable plastic syringe. All formulations contained drug as 2 mg/ml.

Sample collection

At several intermissions (0, 0.5, 1, 2, 4, 8, 12 and 24 h), 2 ml

LC-MS/MS assay of DIC

Plasma samples were analyzed for DIC using a reproducible, sensitive and accurate liquid chromatography-tandem mass spectroscopy (LC-MS/MS) method. Method was developed and validated prior to the analysis. LC system (agilent, Germany) with a quaternary pump and autosampler was coupled with a triple quadripole MS/MS detector. The chromatographic separation was performed on akinetex C18 column 50 \times 4.6 mm and particle size of 2.6 μ m (Phenomenex, Inc., Torrance, CA). The mobile phase consisted of methanol :0.1%

formic acid 80:20 (v/v) was delivered into the MS's electrospray chamber at a flow rate of 0.4 ml/min. The ion spray voltage was adjusted at 3000 V. The common parameters were as follows: nebulizer gas pressure was 45 psi, gas temperature was 275 °C and gas flow rate was 8 l/min. The analysis was carried out at the multiple reaction monitoring (MRM) mode, and its MS parameters were as follows: precursor ion (Da) was 254.1 and 326.5 for DIC and tolterodine, respectively, whereas product ion (Da) was 44.2 and 147.2 for DIC and tolterodine, respectively (El-Mahrouk *et al.*, 2014).

Pharmacokinetic analysis

Pharmacokinetic parameters were estimated from plasma data using computer program WinNonlin (version 1.5, Scientific consulting, Inc., Rockville, MD). Non-compartmental pharmacokinetic model was adopted for the calculation of the maximum drug concentration (C_{max} , ng/ml) and time needed to reach this concentration (T_{max} , h) from each rabbit plasma concentration-time curve. Trapezoidal rule method was adopted for calculation of the area under the curve (AUC) from 0 to 24 (AUC_{0-24} , ng h/ml) and from 0 to infinity ($AUC_{0-\infty}$, ng h/ml). The latter can be calculated from AUC_{0-24} , where $AUC_{0-\infty} = \frac{1}{4} AUC_{0-24} + C^*/k$; C^* is the last

measured concentration and k is the terminal elimination rate constant.

Terminal elimination half-life ($t_{1/2}$) can be calculated from k as $t_{1/2} = 0.693/k$. Finally, relative bioavailability (F_{rel}) for both rectal formulations can be assessed, considering oral formulation as a standard, from the following formula:

$$F_{rel} = \frac{AUC_{test}}{AUC_{standard}} \times 100$$

blood samples was collected into heparinized tubes from the marginal ear vein of the rabbits. Blood samples were centrifuged at 5000 rpm for 30 min for complete separation of

the plasma which were stored at -20°C till analysis.

Samples preparation for analysis

A calibration curve of DIC in plasma was conducted over the range of 0.1–200 ng/ml. A solvent extraction procedure for extraction of drug was performed. Fifty microliters of tolterodine (as internal standard) were mixed with 0.5 ml plasma and vortexed for 30 sec. In all samples 5 ml of ethyl acetate:hexane (90:10 v/v) mixture was added and samples were vortexed again for 1 min and centrifuged for 5 min at 4000 rpm.

Statistical analysis

Mean differences were considered statistically significant at a level $p < 0.05$.

All calculations were performed using the computer program SPSS 16 (SPSS, Chicago, IL). All experiments were done at $n = 3$ and data were presented as mean value \pm SD.

Table 1: Composition, entrapment efficiency, vesicle diameter and *ex vivo* permeation parameters of DIC-loaded nanotransfersomes

Formula	EA used	Composition (PC:EA)	EE (%)	Vesicle diameter (nm)	Q _{24h} (mg/cm)	J (mg/cm ² h)	Lag time (min)	K _p (cm/h)
F1	Span 80	95:5	60.16 ± 1.59	253.97 ± 6.6	198.36 ± 3.55	8.27 ± 0.15	30 ± 3.14	0.004469 ± 0.0007
F2	Span 80	85:15	56.74 ± 0.97	237.66 ± 7.1	222.80 ± 4.19	9.28 ± 0.18	23 ± 1.08	0.004873 ± 0.0009
F3	Span 80	75:25	58.83 ± 1.74	191.90 ± 3.5	166.19 ± 2.89	6.92 ± 0.13	24 ± 1.43	0.003899 ± 0.0008
F4	Tween 80	95:5	55.63 ± 2.04	198.87 ± 2.3	280.71 ± 2.20	11.69 ± 0.09	28 ± 2.13	0.01624 ± 0.0039
F5	Tween 80	85:15	52.39 ± 1.13	150.33 ± 2.8	411.49 ± 5.33	17.15 ± 0.22	11 ± 1.99	0.03628 ± 0.0078
F6	Tween 80	75:25	45.80 ± 1.55	145.03 ± 3.6	329.69 ± 4.71	13.74 ± 0.19	13 ± 3.60	0.01764 ± 0.0112
F7	Brij 35	95:5	43.21 ± 2.33	175.47 ± 1.1	324.67 ± 4.58	13.53 ± 0.19	15 ± 2.78	0.02668 ± 0.0130
F8	Brij 35	85:15	42.83 ± 1.45	149.73 ± 1.7	336.85 ± 3.48	14.04 ± 0.15	9 ± 1.72	0.03552 ± 0.0085
F9	Brij 35	75:25	39.18 ± 1.99	148.27 ± 2.2	333.79 ± 5.11	13.91 ± 0.21	10 ± 2.22	0.03073 ± 0.0127
F10	SDC	95:5	64.59 ± 1.40	253.23 ± 5.1	222.62 ± 3.25	9.28 ± 0.14	32 ± 3.01	0.01183 ± 0.0083
F11	SDC	85:15	44.33 ± 1.17	144.10 ± 8.6	233.96 ± 4.74	9.75 ± 0.20	19 ± 2.95	0.02419 ± 0.0074
F12	SDC	75:25	42.49 ± 2.18	255.55 ± 2.1	210.25 ± 3.69	8.76 ± 0.15	23 ± 1.44	0.01309 ± 0.0059
DIC solution	-	-	-	-	105.54 ± 4.13	4.39 ± 0.18	13 ± 2.56	0.00187 ± 0.0004

PC: phosphatidylcholine; EA: edge activator; SDC: sodium deoxycholate.

Q_{24h}: Cumulative amount of DIC permeated per unit area; J: The flux of the drug; K_p: permeation coefficient. Listed data are mean values ± SD (n = 3).

RESULTS AND DISCUSSION

Entrapment efficiency

Being hydrophilic, DIC would be incorporated into the internal aqueous core of vesicles as suggested by Lopes *et al.* (2004).

The EE% of DIC in different transfersomal formulations was in the range of 39.18–64.59%, as shown in Table 1. EE

varied with different types of EAs used and its concentration relative to PC. With regard to PC:EA ratio, the ratio of 95:5%w/w gave the highest EE% irrespective to the type of EAs. By increasing the concentration of EAs to 15%, the EE% was decreased and further increase in the concentration of the EAs was accompanied with a further decrease in the EE%.

This could be attributed to the growth in the vesicles size as a result of association of EA molecules with phospholipid bilayer.

This growth was, initially, accompanied with incorporation of a high amount of drug.

Further addition of EA may lead to formation of pores in the lipid bilayer. Further increase beyond 15% lead to the formation of rigid small-sized micelles along with vesicles with the consequence of a lower EE (El-Zaafarany *et al.*, 2010).

Furthermore, the ratio of maximum EE (95:5%) was compared in formulations with different EAs for investigation of the effect of different types of EAs on EE. SDC showed the highest EE (64.59%) followed by Span 80 (60.16%), Tween 80 (55.63%) and finally Brij 35 (43.21%). Generally, these results could be explained on the basis of hydrophile-lipophile balance (HLB) values of the EAs used. They are 16.7, 4.3, 15 and 16.9 for SDC, Span 80, Tween 80 and Brij 35, respectively. HLB

values depend on the alkyl chain length of EAs, where the longer the alkyl chain, the lower HLB values and the higher EE % (Hao *et al.*, 2002; Abdelbary & El-Gendy, 2008). The matter that is consistent with our results. Unexpectedly, SDC-based transfersomes gave the highest EE.

A possible explanation may be due to the anionic nature of deoxycholate that impart negative charge on the vesicles leading to generation of a high repulsive force between the lamellae. Thus, the size of the internal aqueous core increased with the consequence of higher EE of the hydrophilic drug DIC (González-Rodríguez *et al.*, 2016).

Moreover, cholesterol was added with a fixed amount to all formulations with the intent of improving the encapsulation efficiency of hydrophilic drugs by stabilizing the bilayer membrane and so prevent leakiness of the drug from the aqueous core (Abdelbary & El-Gendy, 2008; Elhissi *et al.*, 2012; González-Rodríguez *et al.*, 2016).

Particle size and PDI

The mean size of the prepared transfersomal formulations was measured and found to be in the range of 144.10–282.20 nm as shown in Table 1. The results indicated that particle size decreases on increasing the concentration of EAs. Thus, higher

concentration of EAs provided particles with a smaller size that might be attributed to the availability of a high amount of EA that can cover the particle surface, decreasing their interfacial tension and so decreasing their particle size. Similar results were obtained by Al-Mahallawi *et al.* (2014) and Salama *et al.* (2012).

They are 4.3, 15, 16.9 and 16.7 for Span 80, Tween 80, Brij 35 and SDC, respectively. Particle size increases along with decrease in the HLB value. As the EA with higher HLB undergoes interaction with the inner aqueous phase which decrease the particle size. On the other hand, EA with low HLB value undergoes interaction with the lipid head groups of the membrane increasing the packing density of the bilayer and increasing the surface free energy.

As a result, fusion between the lipid bilayer would occur and so the particle size is increased. Thus, the longer the chain length of EA, the lower the HLB value and the larger the particle size. SDC-based vesicles seem to deviate from this explanation that could be attributed to the anionic nature that imparts negative charge on the vesicles leading to generation of a high repulsive force between the lamellae. Thus, the size of the internal aqueous core increased with the consequence of higher

particle size, as previously mentioned.

Our results agreed with previous studies demonstrated the effect of the HLB of surfactant on the particle size of drug-loaded transfersomes (Abdelbary & El-Gendy, 2008; Khan *et al.*, 2014; Ali *et al.*, 2015), which all encapsulate water-soluble drugs. But disagree with other studies incorporating water-insoluble drugs (Yusuf *et al.*, 2014; Aboud *et al.*, 2015).

PDI was used to evaluate the homogeneity of the vesicular dispersions. A value of 0 specifies a monodispersed particles within the system, whereas a value of 1 specifies a highly polydispersed system (Zeisig *et al.*, 1996). PDI of DIC-loaded transfersomes ranged from 0.252 to 0.638 that indicates a good size distribution and satisfying homogeneity of the formulations (data not mentioned).

In vitro release studies

The percentage of DIC released after 8 h (Q_{8h}) from different transfersomal formulations, in comparison with that of DIC solution as a control, is represented graphically in Figure 1(a and b). The release of DIC from control is markedly faster than that from vesicles which may be attributed to the well-known reservoir effect of vesicular systems that provides a sustained release profile (Ghanbarzadeh & Arami, 2013;

Shaji & Lal, 2014). Moreover, the high Q_{8h} of control (97.7%) as well Q_{8h} of some formulations clearly confirms that the membrane used in the experiment did not hinder the drug release and the sink condition was completely accomplished.

The change of Q_{8h} with EAs concentration might be attributed to the hindrance of drug release at both low (5%) and high concentration (25%) of EAs caused by the presence of the membrane bilayer in a more ordered, less leaky form which hinder drug release at low concentration and loss of the vesicular structure along with formation of a rigid mixed micelles at high concentration. Mixed micelles were reported to be less sensitive to the water activity gradient than transfersomes (El-Maghraby *et al.*, 2000; Jain *et al.*, 2003).

On the other hand, the PC:EA with the ratio (85:15% w/w) produces vesicles with a higher Q_{8h} due to association of EAs molecules with the phospholipid bilayer to provide better partitioning of the drug (Gupta *et al.*, 2012). Thus, formulations, prepared using this ratio, were selected to demonstrate the effect of different EAs on Q_{8h} .

The Q_{8h} was 93.69, 92.52, 84.03 and 37.32%, respectively, for Brij 35, Tween 80, SDC and Span 80 based transfersomes. One way to explain these results is to consider

the fact that vesicles exhibit alky chain-length-dependent drug release. The higher the EA chain length, the lower the drugs release. The difference in the alkyl chain might induce variations in the molecular ordering of the vesicles that affect the release rate (Hosny & Hassan, 2014).

Another way to explain these results is to consider their particle size, where small particle size provides a larger surface area exposed to the release medium and thus enhance the drug release (Abdelbary & El-Gendy, 2008; El-Zaafarany *et al.*, 2010; Aboud *et al.*, 2015).

Our results agree with El-Zaafarany *et al.* who reported that the release of diclofenac sodium from transfersomes was in the order: Tween 804SDC4SC4Span 804Span 85 (El-Zaafarany *et al.*, 2010) and agree with Abdelbary and El-gendy who reported that the release of gentamicin sulfate from niosomes was in the order: Brij 354Tween 804Tween 60 (Abdelbary & El-Gendy, 2008).

Ex vivo permeation studies

Permeation of molecules across biological membranes is a multistep, multifactorial phenomenon depending on various types of chemical, physical and biological interactions. However, the ex vivo permeation studies provide a valuable

insight on the in vivo performance of many products (Ammar *et al.*, 2009). The rectum is known to have a similar epithelium to that of the upper GI tract and the predominant mechanism of permeation through the rectal mucosa appears to involve transcellular passage across the cell membrane (Kamel *et al.*, 2013). The calculated permeation parameters, listed in Table 1, were used to assess the permeation efficiency of the tested transfersomal formulations against DIC solution.

Generally, transfersomal formulations showed a higher permeation, the matter that could be attributed to their composition of phospholipid and EAs. EA imparts deformability to the membrane bilayer of the vesicles, thereby facilitating their passage across rectal epithelial. Moreover, phospholipids were reported to have high affinity for biological membranes that contribute to enhancement of the permeation efficiency (El-Zaafarany *et al.*, 2010; González-Rodríguez *et al.*, 2016).

Based on Q_{24h} , transfersomes with high (25% w/w) and low (5% w/w) concentration of EAs were not beneficial in vesicular drug delivery, whereas those containing the middle (15% w/w) concentration of EAs showed a higher permeability profiles, irrespective of the

EA type.

Upon comparing the ratio of maximum Q_{24h} (85:15), formulation containing Tween 80 showed the highest Q_{24h}, followed by Brij 35, SDC and finally Span 80 containing transfersomes.

Moreover, difference in the particle size between the mentioned formulations might play a role in the permeation across the biological membrane. The reduced dimensions of the vesicles could positively influence their permeation (Bragagni *et al.*, 2012). These results correlate well with those obtained from the *in vitro* release studies.

Morphology of DIC vesicles

TEM analysis provides a useful mean for examination of the morphology of colloidal systems and also in confirming the results obtained by size analysis (Lim *et al.*, 2014). Transmission electron micrograph of the optimum formula displayed a non-aggregated, well-identified unilamellar and spherical-shaped vesicles with a large internal aqueous core (**Figure 2**).

Histopathological studies

The histopathological evaluation was performed to inspect any irritation or damage to the rectal mucosa of rats after administration of TG and FG as compared to

the control (**Figure 3**). In this study, normal healthy rectal mucosa without administration was used as a control (**Figure 3a**). Rectal tissues of group B showed focal massive leukocytosis inside the submucosa associated with hemorrhage and mild congested blood capillaries that may be attributed to the acidic nature of the free DIC (**Figure 3b**).

On the other hand, rectal tissues of group C showed no signs of damage or irritation and tissues appeared to be more or less normal as compared to the control (**Figure 3c**). Thus, current evaluation suggests that transfersomes-loaded *in situ* gel might therefore be regarded as safe.

In vivo pharmacokinetics studies

The LC-MS/MS method was used to estimate the pharmacokinetic parameters of DIC in rabbit plasma to investigate the *in vivo* behavior of the TG formula as compared with FG formula and oral drug solution as a standard. The LC-MS/MS method was validated and confirmed good linearity from 0.1 to 200 ng/ml.

The mean plasma concentration-time profiles of DIC following administration of oral solution, rectal FG and rectal TG are illustrated in **Figure 4** and the corresponding pharmacokinetic parameters are outlined in Table 2. As shown, DIC was immediately absorbed and reached

maximal concentration, C_{max} , of 75.04 ng/ml at 0.5 h after oral administration of the drug solution. Then, concentration of DIC was remarkably decreased in the following hours. The maximum concentration of 43.16 ng/ml and 144.31 ng/ml was reached at 0.75 h and 1 h for FG and TG, respectively. Compared to oral solution, the relative bioavailability calculated from AUC_{0-1} was found to be 218.73% and 138.24%, respectively, for TG and FG which is considered a remarkable enhancement in

($t_{1/2}$) of both rectal formulations indicated retardation in the DIC release caused by the use of gel system, whereas higher retardation exerted by TG formula may be attributed to the dual sustained effect caused by both vesicular and gelling system.

These results are in good agreement with the in vitro release data of the drug. In conclusion, the significant increase in AUC_{0-1} , F_{rel} and $t_{1/2}$ of in situ gelling nanotransfersomal formulation of DIC indicates that an excellent increase in the bioavailability and a sustained




Figure 1: *In vitro* release profiles of DIC from drug solution and transfersomal formulae: (A) F1–F6 and (B) F7–F12.




Figure 2: Transmission electron micrograph of freshly prepared transfersomal formula F5.




Figure 3: Morphology of rabbit rectal mucosa: (A) control, (B) 8 h after administration of FG and (C) 8 h after administration of TG.




Figure 4. Mean DIC concentrations in rabbit plasma following administration of oral solution, rectal DIC in situ gel (FG) and rectal transfersomal in situ gel (TG).

Table 2: Pharmacokinetic parameters of DIC in rabbit plasma following administration of oral solution, FG and TG

Ke (h^{-1})	0.203 ± 0.07	0.0962 ± 0.001	0.0692 ± 0.0074
$t_{1/2}$ (h)	3.41 ± 0.89	7.21 ± 0.04	10.13 ± 1.08
AUC ₀₋₂₄ (ng h/ml)	164.13 ± 7.58	204.23 ± 20.90	314.68 ± 12.72
AUC ₀₋₁ (ng h/ml)	173.49 ± 16.61	239.83 ± 28.11	379.48 ± 21.92
MRT (h)	4.71 ± 0.99	10.93 ± 0.53	12.03 ± 2.03
Frel (%)	100	138.24	218.73

C_{max}: maximum drug concentration in plasma; T_{max}: time to reach C_{max}; Ke: elimination rate constant; t_{1/2}: terminal half-life; AUC₀₋₂₄: area under plasma concentration–time curve from 0 to 24 h; AUC₀₋₁: total area under plasma concentration–time curve; MRT: mean residence time; Frel: relative bioavailability. Listed data are mean values \pm SD (n = 3).

CONCLUSION

Thus, the developed transfersomal formula could be considered as a promising rectal delivery system of DIC that could bypass the hepatic first-pass metabolism, enhancing DIC bioavailability, control its release with the consequence of reduced frequency of DIC administration and improved the patient compliance.

REFERENCES

- [1] Abdelbary G, El-Gendy N. (2008). Niosome-encapsulated gentamicin for ophthalmic controlled delivery. *AAPS PharmSciTech* 9: 740–7.
- [2] Abdelrahman AA, Salem HF, Khallaf RA, Ali AMA. (2015). Modeling, optimization, and in vitro corneal permeation of chitosan-lomefloxacin HCl nanosuspension intended for ophthalmic delivery. *J Pharm Innov* 10:254–68.
- [3] Aboud HM, Ali AA, El-Menshawe SF, Elbary AA. (2015). Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation. *Drug Deliv* 1–11. doi:10.3109/10717544.2015.1013587.
- [4] Al-Mahallawi AM, Khowessah OM, Shoukri RA. (2014). Nanotransfersomal ciprofloxacin loaded vesicles for noninvasive trans-tympanic ototopical delivery: in-vitro optimization, ex-vivo permeation studies, and in-vivo assessment. *Int J Pharm* 472:304–14.
- [5] Ali MFM, Salem HF, Abdelmohsen HF, Attia SK. (2015). Preparation and clinical evaluation of nanotransfersomes for treatment of erectile dysfunction. *Drug Des Dev Ther* 9:2431–47.
- [6] Ammar HO, Ghorab M, El-Nahhas SA, Kamel R. (2009). Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part II: biological evaluation. *AAPS PharmSciTech* 10:1065–70.
- [7] Baldrick P. (2000). Pharmaceutical excipient development: the need for preclinical guidance. *Regul Toxicol Pharmacol* 32:210–18.
- [8] Bragagni M, Mennini N, Maestrelli F, *et al.* (2012). Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. *Drug Deliv* 19:354–61.
- [9] Cevc G, Blume G. (2003). Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes®. *Biochim Biophys Acta* 1614:156–64.
- [10] Cevc G, Blume G, Schätzlein A. (1997). Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo. *J Control*

- Release 45:211–26.
- [11] El-Kamel A, El-Khatib M. (2006). Thermally reversible in situ gelling carbamazepine liquid suppository. *Drug Deliv* 13:143–8.
- [12] El-Leithy ES, Shaker DS, Ghorab MK, Abdel-Rashid RS. (2010). Evaluation of mucoadhesive hydrogels loaded with diclofenac sodium–chitosan microspheres for rectal administration. *AAPS Pharmscitech* 11:1695–702.
- [13] El-Mahrouk GM, El-Gazayerly ON, Aboelwafa AA, Taha MS. (2014). Chitosan lactate wafer as a platform for the buccal delivery of Dicyclomine HCl: in vitro and in vivo performance. *Int J Pharm* 467: 100–12.
- [14] El-Maghraby GM, Williams AC, Barry BW. (2000). Estradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. *Int J Pharm* 196:63–74.
- [15] El-Zaafarany GM, Awad GA, Holayel SM, Mortada ND. (2010). Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. *Int J Pharm* 397:164–72.
- [16] Elhissi AM, Giebultowicz J, Stec AA, *et al.* (2012). Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients. *Int J Pharm* 436:519–26.
- [17] Ghanbarzadeh S, Arami S. (2013). Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. *BioMed Res Int* 2013:1–7. doi:10.1155/2013/616810.
- [18] Hao Y, Zhao F, Li N, *et al.* (2002). Studies on a high encapsulation of colchicine by a niosome system. *Int J Pharm* 244:73–80.
- [19] Hosny KM, Hassan AH. (2014). Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation. *Int J Pharm* 475:191–7.
- [20] Huang C, Tokumura T, Machida Y, Nagai T. (1987). Formulation of double-layered suppository for prolonged stay in lower rectum. *Yakuzaigaku* 47:42–8.
- [21] Jain S, Jain P, Uma Maheshwari R, Jain N. (2003). Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. *Drug Dev Indus Pharm* 29:1013–26.
- [22] Kamel R, Basha M, Abd El-Alim SH. (2013). Development of a novel vesicular system using a binary mixture of sorbitan monostearate and polyethylene glycol fatty acid esters for rectal delivery of rutin. *J Liposome Res*

- 23:28–36.
- [23] Khan MA, Pandit J, Sultana Y, *et al.* (2014). Novel carbopol-based transfersomal gel of 5-fluorouracil for skin cancer treatment: in vitro characterization and in vivo study. *Drug Deliv* 22:795–802.
- [24] Lim WM, Rajinikanth PS, Mallikarjun C, Kang YB. (2014). Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. *Int J Nanomedicine* 9:2117.
- [25] Lopes L, Scarpa M, Silva G, *et al.* (2004). Studies on the encapsulation of diclofenac in small unilamellar liposomes of soya phosphatidylcholine. *Colloids Surf B Biointerfaces* 39:151–8.
- [26] Mahmood S, Taher M, Mandal UK. (2014). Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. *Int J Nanomedicine* 9:4331–46.
- [27] Miyazaki S, Suisha F, Kawasaki N, *et al.* (1998). Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. *J Control Release* 56:75–83.
- [28] Ö zgüney I, Kardhiqi A, Yildiz G, Ertan G. (2014). In vitro-in vivo evaluation of in situ gelling and thermosensitive ketoprofen liquid suppositories. *Eur J Drug Metab Pharmacokinet* 39:283–91.
- [29] Pan W, Yang Z. (2011). Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. *Int J Nanomedicine* 6:151–66.
- [30] Pendekal MS, Tegginamat PK. (2012). Formulation and evaluation of a bioadhesive patch for buccal delivery of Dicyclomine. *Acta Pharm*
- [31] Sin B 2:318–24.
- [32] Salama HA, Mahmoud AA, Kamel AO, *et al.* (2012). Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. *J Liposome Res* 22:336–45.
- [33] Schmolka IR. (1972). Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. *J Biomed Mater Res* 6: 571–82.
- [34] Shaji J, Lal M. (2014). Preparation, Optimization and evaluation of transferosomal formulation for enhanced transdermal delivery of a COX-2 Inhibitor. *Int J Pharm Pharmaceut Sci* 6:467–77.
- [35] Ud Din F, Mustapha O, Kim DW, *et al.* (2015). Novel dual-reverse thermosensitive solid lipid nanoparticle-loaded hydrogel for rectal administration of flurbiprofen

- with improved bioavailability and reduced initial burst effect. *Eur J Pharm Biopharm* 94:64–72.
- [36] Wagstaff AJ, Bryson HM. (1997). Dicyclomine. A review of its pharmacology, clinical efficacy and tolerability in the management
- [37] of spasticity associated with cerebral and spinal disorders. *Drugs* 53: 435–52.
- [38] Yang X, Shah SJ, Wang Z, *et al.* (2015). Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir. *Drug Deliv* 1–11. doi:10.3109/10717544.2014.996833.
- [39] Yusuf M, Sharma V, Pathak K. (2014). Nanovesicles for transdermal delivery of felodipine: development, characterization, and pharmacokinetics. *Int J Pharm Investig* 4:119–30.
- [40] Zeisig R, Shimada K, Hirota S, Arndt D. (1996). Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines. *Biochim Biophys Acta* 1285:237–45.